Context:

Eli Lilly won its first regulatory approval outside the U.S. for the weight‑loss drug orforglipron (Foundayo) in the U.K., placing it in competition with Novo Nordisk’s Wegovy pill two months after Wegovy’s UK launch. The approval, for weight management and type 2 diabetes, will be subject to cost‑effectiveness review by NICE before NHS reimbursement. Lilly emphasizes that Foundayo is a small‑molecule medicine that can be taken without strict food restrictions, contrasting with Wegovy’s strict dosing. The development highlights a widening appetite for oral weight‑loss options, as both companies push to establish a new pill‑driven segment and broaden the market beyond existing injectables.

Dive Deeper:

• The U.K. Medicines and Healthcare products Regulatory Agency authorized orforglipron, sold as Foundayo, for weight management and type 2 diabetes on prescription, with NICE to assess cost‑effectiveness for NHS access.

• This marks Lilly’s first outbound regulatory approval for Foundayo, aimed at competing with Novo Nordisk’s Wegovy pill, which launched in the U.K. a couple of months earlier.

• Wegovy’s oral pill uses the same active ingredient, semaglutide, as its injectable forms, while Foundayo is presented as a small‑molecule option that removes certain food‑restrictions associated with Wegovy.

• In the U.S., Foundayo entered the market in April and posted $98 million in sales in the second quarter, signaling early demand despite a slower uptake than Wegovy.

• Novo CEO Mike Nick names the early UK uptake of Wegovy at roughly 300,000 patients in the first three weeks, illustrating rapid market momentum for the oral format already.

• Both companies frame the trend as market expansion rather than a shift from injectables to pills, with executives signaling that the new pill option could broaden the overall weight‑loss market.

• Lilly CEO David Ricks noted that Foundayo’ s adoption will take time as doctors and patients acclimate to a completely new medicine.